Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of lung cancer (non-small cell lung cancer, or NSCLC) at stage II through IIIB, confirmed through laboratory testing of tissue, where surgery with the aim of curing the cancer is considered possible
- People whose cancer can be measured using standard imaging criteria (known as RECIST 1.1)
- People who have a stored tumour tissue sample (preserved in a specific way) available to send to the trial team
- People who are relatively active and able to carry out daily activities, rated 0 or 1 on a standard health and activity scale (ECOG scale — confirm with trial site for exact details)
- People whose organs (such as kidneys and liver) and bone marrow are functioning well enough, as assessed by the trial team
Who may not be able to join:
- People who have already received systemic cancer treatment or radiotherapy for this current tumour
- People whose tumour has specific genetic changes (in genes called EGFR or ALK) that are already known before joining the trial
- People who have moderate to severe nerve damage in their hands or feet (grade 2 or higher peripheral neuropathy)
- People who have another cancer that is currently growing or requires active treatment
- People assigned to Arm 1 of the trial who have severely high calcium levels in their blood (grade 3 or higher)
- People assigned to Arm 1 who have certain conditions affecting the brain or nervous system that could raise the risk of a specific type of nerve-related side effect (confirm with trial site for exact details)
- People assigned to Arm 1 who have a notably abnormal heart rhythm reading on an ECG, or risk factors for a particular heart rhythm issue (confirm with trial site for exact details)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals
Phone: 844-734-6643
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Major pathologic response (MPR) rate as determined by central blinded independent pathology review (BIPR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.